SynthesisDiabetes care2025
Type 2 Diabetes Remission: A Systematic Review and Meta-analysis of Nonsurgical Randomized Controlled Trials.
Synthesis in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07665567 (Remission Evaluation of Metabolic Interventions in Type 2 Diabetes in Primary Care), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes in Primary Care (REMIT-Prime): An Implementation-effectiveness Study
Who cites it
4 citing papers in PubMed.
- Laparoscopic sleeve gastrectomy versus conventional medical therapy in patients with newly diagnosed type 2 diabetes and body mass index 30-42 Kg/mJournal of endocrinological investigation · 2026Article
- Review
- Adapting the Dutch Reverse Diabetes2 Now program for Belgian primary care: a quasi-experimental study of effectiveness and transferability.Archives of public health = Archives belges de sante publique · 2026Article
- Clinical and Metabolic Characteristics of Spontaneous Remission in Type 2 Diabetes: A Real-World Study from South India.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundEvidence that type 2 diabetes can be reversed has been limited by the understanding and implementation of these interventions. PURPOSE: We assessed the effect of nonsurgical randomized controlled trials (RCTs) on type 2 diabetes remission and characterized core components. DATA SOURCES: We reviewed articles from MEDLINE and Embase (inception to April 2025). STUDY SELECTION: RCTs of multimodal pharmacological or nonpharmacological type 2 diabetes remission interventions for adults with type 2 diabetes were included. DATA EXTRACTION: Study characteristics and outcomes for clinical/population health, patient-reported, and adverse event were extracted. DATA SYNTHESIS: We performed a random-effects multilevel meta-analysis of studies, grouped based on type of intervention and by length of follow-up. A total of 18 studies were included in this review from 11 different countries. There was a higher likelihood of achieving type 2 diabetes remission through multimodal interventions (risk ratio [RR] 1.75 [95% CI 1.49-2.04]) and for nonpharmacological interventions (RR 5.80 [95% CI 4.28-7.87]), compared with the control group. Other significant outcomes for intervention groups compared with control groups included change in A1C, weight loss, and quality of life and improvements in adverse events of hypoglycemia. LIMITATIONS: There was heterogeneity in our small pool of included studies (diversity of nonpharmacological components), stringent intervention protocols, narrow participant selection criteria, and lack of consistent diabetes remission definitions.
conclusionsWith specific protocols, a variety of tailored approaches can induce type 2 diabetes remission for patients with newly diagnosed type 2 diabetes who are able to subscribe to strict protocols. Consideration of long-term sustainability and effectiveness is needed in future research, along with patient preferences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.